Posted by Michael Wonder on 13 Mar 2025
First licensed treatment for ultra-rare immune disorder recommended
13 March 2025 - Leniolisib is the first ever treatment for activated phosphoinositide 3-kinase delta syndrome licensed for use in the NHS in England.
In final draft guidance published today, we have recommended leniolisib (Joenja; Pharming) for treating activated phosphoinositide 3-kinase delta syndrome, an ultra-rare inherited immune system disorder, in people 12 years and over.
